425: Boston Scientific to Acquire Penumbra for $14.5 Billion

Boston Scientific announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, expanding its cardiovascular and neurovascular portfolios.

Summary

• Boston Scientific Corporation (BSX) has entered into a definitive agreement to acquire Penumbra, Inc. (PEN) for an enterprise value of approximately $14.5 billion.
• The transaction values each Penumbra share at $374, with stockholders having the option to elect cash or Boston Scientific common stock, subject to proration.
• The total consideration will be paid approximately 73% in cash and 27% in Boston Scientific shares.
• Boston Scientific expects to finance the approximately $11 billion cash portion with a combination of cash on hand and new debt.
• The acquisition is anticipated to be $0.06-$0.08 dilutive to Boston Scientific's adjusted earnings per share in the first full year post-close, becoming neutral to slightly accretive in the second year and more accretive thereafter.
• Penumbra's preliminary Q4 2025 reported revenue growth is expected to be in the range of 21.4% 22.0%, with full year 2025 reported revenue of approximately $1.4 billion, representing 17.3% 17.5% growth over the prior fiscal year.
• Penumbra's preliminary full year 2025 estimated gross margin is 67.9% 68.1% and operating margin is 13.3% 13.6%.
• The transaction is expected to close in 2026, pending Penumbra stockholder approval and customary closing conditions.
• Adam Elsesser, Penumbra's Chairman and CEO, will join Boston Scientific's board of directors upon closing and will elect to receive Boston Scientific shares for all his Penumbra shares.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the strategic nature of the acquisition, entry into high-growth markets, and long-term accretion potential, despite initial EPS dilution. The strong financial profile of Penumbra and the integration of its CEO into Boston Scientific's board further bolster confidence.

Positives

• The acquisition provides Boston Scientific with a scaled entry into new, fast-growing segments within the vascular space, specifically mechanical thrombectomy and neurovascular.
• It expands Boston Scientific's cardiovascular portfolio, addressing the increasing prevalence of vascular diseases globally.
• The addition of Penumbra's differentiated devices for conditions like pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack, and aneurysms enhances Boston Scientific's product offerings.
• The transaction is expected to enhance Boston Scientific's revenue and margins over time, with Penumbra having a history of growth and innovation.
• Penumbra's portfolio and pipeline are in high-growth adjacent areas with a weighted average market growth rate (WAMGR) of 11%.
• The acquisition leverages Boston Scientific's capabilities, including its supply chain and global footprint, to expand access for Penumbra's technologies to more patients and customers worldwide.
• Penumbra's preliminary financial results for Q4 and FY 2025 show strong revenue growth and healthy margins, indicating a profitable growth profile.
• Adam Elsesser, Penumbra's Chairman and CEO, joining Boston Scientific's board ensures continuity and integration of leadership.

Negatives

• The transaction is expected to be dilutive to Boston Scientific's adjusted earnings per share by $0.06-$0.08 in the first full year following the close of the acquisition.
• GAAP earnings per share are also expected to be dilutive in the first full year due to amortization expense and acquisition-related net charges.

Risks

• Economic conditions, including the impact of foreign currency fluctuations, could affect actual results.
• Future U.S. and global political, competitive, reimbursement, and regulatory conditions, including changing trade and tariff policies, pose risks.
• Geopolitical events, manufacturing, distribution, and supply chain disruptions, and cost increases could impact operations.
• Disruptions caused by cybersecurity events, public health emergencies, extreme weather, or other climate change-related events are potential challenges.
• Labor shortages and increases in labor costs could affect financial performance.
• Variations in outcomes of ongoing and future clinical trials and market studies may impact product success.
• The ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Penumbra's operations is not guaranteed.
• Business disruptions, including those affecting relationships with employees, customers, or suppliers, could occur following the announcement and/or closing of the transaction.
• The conditions to the completion of the proposed transaction, including the receipt of required regulatory approvals and clearances, may not be satisfied at all or in a timely manner.
• The closing of the proposed transaction may not occur or may be delayed.

Future Outlook

The transaction is expected to be completed in 2026, subject to Penumbra's stockholder approval and customary closing conditions. Boston Scientific anticipates the acquisition will be dilutive to adjusted EPS in the first full year, neutral to slightly accretive in the second year, and more accretive thereafter, contributing to long-term revenue and margin enhancement.

Management Comments

• Mike Mahoney, Chairman and CEO of Boston Scientific, stated, "I'm thrilled to combine the talents and shared values of our teams including welcoming Penumbra's chairman and chief executive officer, Adam Elsesser, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation."
• Adam Elsesser, Chairman and CEO of Penumbra, expressed, "Our decades-long development of therapies for challenging medical conditions has focused on deep innovation for complex diseases so that we can offer physicians novel solutions to transform patient care. I am grateful for the amazing people who have contributed to this work and look forward to uniting our efforts and shared values as we come together with Boston Scientific."

Industry Context

This acquisition positions Boston Scientific to capitalize on the growing global prevalence of cardiovascular diseases, which are the leading cause of death. By integrating Penumbra's innovative mechanical thrombectomy and neurovascular solutions, Boston Scientific gains a significant foothold in fast-growing, underserved segments. This move aligns with a broader industry trend of medical technology companies seeking to expand their portfolios into high-growth therapeutic areas through strategic M&A to address complex medical conditions and improve patient outcomes.

Comparison to Industry Standards

• The filing highlights Penumbra as a 'leader in vascular solutions' and 'the world's leading thrombectomy company,' indicating a strong market position within its specialized segments.
• Penumbra's portfolio is described as having a weighted average market growth rate (WAMGR) of 11% in high-growth adjacent areas, suggesting performance in line with or exceeding growth in these specialized medical device markets.
• The filing does not provide specific comparable company financial metrics or project results from direct competitors to benchmark Penumbra's performance against industry standards.

Management Changes

Stakeholder Impact

• Shareholders of Penumbra will receive $374 per share, with an option for cash or Boston Scientific stock, representing a significant return.
• Shareholders of Boston Scientific will experience initial EPS dilution but are expected to benefit from long-term growth and accretion from the expanded portfolio.
• Employees of Penumbra will become part of Boston Scientific, potentially leading to integration efforts and business disruptions.
• Customers and physicians will gain expanded access to Penumbra's innovative mechanical thrombectomy and neurovascular technologies through Boston Scientific's global reach.
• Creditors of Boston Scientific may see changes in the company's debt profile due to the financing of the cash portion of the acquisition, though Boston Scientific expects to maintain strong credit ratings.

Next Steps

• Boston Scientific will hold a conference call on January 15, 2026, at 8:00 a.m. ET to discuss the transaction.
• Boston Scientific will file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• Penumbra will mail the proxy statement/prospectus to its stockholders.
• Penumbra stockholders must approve the transaction.
• The transaction is subject to the satisfaction of other customary closing conditions, including regulatory approvals and clearances.
• The transaction is expected to be completed in 2026.

Key Dates

Recommendation

This acquisition represents a highly strategic move for Boston Scientific, providing immediate entry into high-growth, underserved segments of the cardiovascular and neurovascular markets. While there is an expected short-term dilution to adjusted EPS, the long-term accretion, significant market opportunity, and Penumbra's strong growth profile and innovative pipeline suggest substantial value creation. The integration of Penumbra's CEO onto Boston Scientific's board further signals a commitment to successful integration and leveraging Penumbra's expertise. This transaction positions Boston Scientific for accelerated growth and market leadership, making it a strong buy for long-term investors.

Keywords

Acquisition, Merger, Medical Technology, Cardiovascular, Neurovascular, Thrombectomy, Embolization, Stroke, Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Medical Devices, Healthcare, Boston Scientific, Penumbra